Kailera Therapeutics priced an upsized US IPO to raise $625 million, with the proceeds earmarked for clinical development of its obesity drug candidates. Coverage notes the company’s obesity-first approach and its China roots, including a pipeline led by ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP dual agonist currently in Phase 3 testing. The financing arrives after earlier venture rounds and is positioned to support global trials for injectable and oral obesity programs. The IPO also places Kailera among the largest recent US biotech offerings, reflecting investor focus on late-stage metabolic franchises. For the sector, the transaction signals that despite funding volatility, investors are still underwriting obesity assets with credible clinical progression and scale-ready manufacturing narratives.